Search

Your search keyword '"Boer, M.A."' showing total 2 results
Start Over Author "Boer, M.A." Journal bmc pregnancy and childbirth vol. 17 no. 1
2 results on '"Boer, M.A."'

1. Low dose aspirin in the prevention of recurrent spontaneous preterm labour - the APRIL study: A multicenter randomized placebo controlled trial

Author

Visser, L. (Laura), de Boer, M.A. (Marjon A.), Groot, C.J.M. (Christianne) de, Nijman, T.A.J. (Tobias A.J.), Hemels, M.A.C. (Marieke A.C.), Bloemenkamp, K.W.M. (Kitty), Bosmans, J.E. (Judith), Kok, M. (Marjolein), van Laar, J.O. (Judith O.), Sueters, M. (Marieke), Scheepers, H.C.J. (Hubertina), van Drongelen, J. (Joris), Franssen, M.T.M. (Maureen), Sikkema, J.M. (J. Marko), Duvekot, J.J. (Hans), Bekker, M.N. (Mireille), Post, J.A.M. (Joris) van der, Naaktgeboren, C. (Christiana), Mol, B.W.J. (Ben), Oudijk, M.A. (Martijn), Visser, L. (Laura), de Boer, M.A. (Marjon A.), Groot, C.J.M. (Christianne) de, Nijman, T.A.J. (Tobias A.J.), Hemels, M.A.C. (Marieke A.C.), Bloemenkamp, K.W.M. (Kitty), Bosmans, J.E. (Judith), Kok, M. (Marjolein), van Laar, J.O. (Judith O.), Sueters, M. (Marieke), Scheepers, H.C.J. (Hubertina), van Drongelen, J. (Joris), Franssen, M.T.M. (Maureen), Sikkema, J.M. (J. Marko), Duvekot, J.J. (Hans), Bekker, M.N. (Mireille), Post, J.A.M. (Joris) van der, Naaktgeboren, C. (Christiana), Mol, B.W.J. (Ben), and Oudijk, M.A. (Martijn)

Abstract

Background: Preterm birth (birth before 37 weeks of gestation) is a major problem in obstetrics and affects an estimated 15 million pregnancies worldwide annually. A history of previous preterm birth is the strongest risk factor for preterm birth, and recurrent spontaneous preterm birth affects more than 2.5 million pregnancies each year. A recent meta-analysis showed possible benefits of the use of low dose aspirin in the prevention of recurrent spontaneous preterm birth. We will assess the (cost-)effectiveness of low dose aspirin in comparison with placebo in the prevention of recurrent spontaneous preterm birth in a randomized clinical trial. Methods/design: Women with a singleton pregnancy and a history of spontaneous preterm birth in a singleton pregnancy (22-37 weeks of gestation) will be asked to participate in a multicenter, randomized, double blinded, placebo controlled trial. Women will be randomized to low dose aspirin (80 mg once daily) or placebo, initiated from 8 to 16 weeks up to maximal 36 weeks of gestation. The primary outcome measure will be preterm birth, defined as birth at a gestational age (GA) < 37 weeks. Secondary outcomes will be a composite of adverse neonatal outcome and maternal outcomes, including subgroups of prematurity, as well as intrauterine growth restriction (IUGR) and costs from a healthcare perspective. Preterm birth will be analyzed as a group, as well as separately for spontaneous or indicated onset. Analysis will be performed by intention to treat. In total, 406 pregnant women have to be randomized to show a reduction of 35% in preterm birth from 36 to 23%. If aspirin is effective in preventing preterm birth, we expect that there will be cost savings, because of the low costs of aspirin. To evaluate this, a cost-effectiveness analysis will be performed comparing preventive treatment with aspirin with placebo. Discussion: This trial will provide evidence as to whether or not low dose aspirin is (cost-) effective in reducing r

Published
2017
Full Text
View/download PDF

2. STRIDER (Sildenafil TheRapy in dismal prognosis early onset fetal growth restriction): An international consortium of randomised placebo-controlled trials

Author

Pels, A. (A.), Kenny, L.C. (Louise C.), Alfirevic, Z. (Zarko), Baker, P.N. (Philip Newton), Dadelszen, P. (Peter) von, Gluud, C. (Christian), Kariya, C.T. (C. T.), Mol, B.W.J. (Ben), Papageorghiou, A. (A.), Wassenaer-Leemhuis, A.G. (Aleid) van, Ganzevoort, W. (Wessel), Groom, K.M. (K. M.), McCowan, L.M. (L. M.), Stone, P.R. (P. R.), Lee, A. (A.), Mackay, L. (L.), Oyston, C. (C.), Gardener, G. (G.), Khashan, A. (A.), Eustace, J. (J.), Dempsey, E. (E.), Jackson, R. (R.), Dickinson, J. (J.), Gill, A. (A.), Muller, P. (P.), Sekar, R. (R.), Reid, R.A. (R. A.), Unterschneider, J. (J.), Welsh, A. (A.), Marlow, J. (J.), Hyett, J. (Jon), Walker, S. (S.), Morris, J., Watson, D. (D.), McKinlay, C. (C.), Harris, S. (S.), von Dadelszen, P. (P.), Lim, K.I. (K. I.), Lalji, S. (S.), Magee, L.A. (L. A.), Lee, T. (T.), Li, J. (J.), Hutfield, A. (A.), Ansermino, M. (M.), Robinson, W. (W.), Singer, J. (J.), Synnes, A.R. (A. R.), Burrows, J. (J.), Audibert, F. (F.), Bujold, E. (Emmanuel), Piedboeuf, B. (B.), Davidge, S.T. (S. T.), Seaward, G.R. (G. R.), Dwinnell, S. (S.), Gagnon, R. (R.), Gaudet, L. (L.), Young, C. (C.), Murphy, D. (D.), Daly, S. (S.), McAuliffe, F. (F.), Malone, F. (F.), Breathnach, F. (F.), O'Donoghue, K. (K.), Ganzevoort, J.W. (J. W.), Al-Nasiry, S. (S.), de Boer, M.A. (M. A.), Groot, C.J.M. (Christianne) de, Sueters, M. (M.), Derks, J.B. (Jan), van Drongelen, J. (J.), Duvekot, J.J. (Hans), Elvan-Taspinar, A. (A.), Eyck, J. (Jim) van, van Laar, J. (J.), Morssink, L.P. (L. P.), Alfirevic, Z. (Z.), Price, L. (L.), Astor, A. (A.), Hardman, L. (L.), Sharp, A. (A.), Turner, M. (M.), Cameron, A. (A.), Draper, E. (E.), Clarke, P. (P.), Mckelvey, A. (A.), Papageorghiou, A.T. (A.), Masson, G. (G.), Aquilin, J. (J.), Johnstone, E. (E.), Bugg, G. (G.), Howe, D. (D.), Patni, S. (S.), Mousa, H. (H.), Russell, H. (H.), Hannon, T. (T.), Kilby, M.D. (Mark), David, A. (A.), Cohen, K. (K.), Impey, L. (L.), Stock, S. (S.), Poon, L. (L.), Pasupath, D. (D.), Khalil, A. (Asma), Baker, P.N. (P. N.), Pels, A. (A.), Kenny, L.C. (Louise C.), Alfirevic, Z. (Zarko), Baker, P.N. (Philip Newton), Dadelszen, P. (Peter) von, Gluud, C. (Christian), Kariya, C.T. (C. T.), Mol, B.W.J. (Ben), Papageorghiou, A. (A.), Wassenaer-Leemhuis, A.G. (Aleid) van, Ganzevoort, W. (Wessel), Groom, K.M. (K. M.), McCowan, L.M. (L. M.), Stone, P.R. (P. R.), Lee, A. (A.), Mackay, L. (L.), Oyston, C. (C.), Gardener, G. (G.), Khashan, A. (A.), Eustace, J. (J.), Dempsey, E. (E.), Jackson, R. (R.), Dickinson, J. (J.), Gill, A. (A.), Muller, P. (P.), Sekar, R. (R.), Reid, R.A. (R. A.), Unterschneider, J. (J.), Welsh, A. (A.), Marlow, J. (J.), Hyett, J. (Jon), Walker, S. (S.), Morris, J., Watson, D. (D.), McKinlay, C. (C.), Harris, S. (S.), von Dadelszen, P. (P.), Lim, K.I. (K. I.), Lalji, S. (S.), Magee, L.A. (L. A.), Lee, T. (T.), Li, J. (J.), Hutfield, A. (A.), Ansermino, M. (M.), Robinson, W. (W.), Singer, J. (J.), Synnes, A.R. (A. R.), Burrows, J. (J.), Audibert, F. (F.), Bujold, E. (Emmanuel), Piedboeuf, B. (B.), Davidge, S.T. (S. T.), Seaward, G.R. (G. R.), Dwinnell, S. (S.), Gagnon, R. (R.), Gaudet, L. (L.), Young, C. (C.), Murphy, D. (D.), Daly, S. (S.), McAuliffe, F. (F.), Malone, F. (F.), Breathnach, F. (F.), O'Donoghue, K. (K.), Ganzevoort, J.W. (J. W.), Al-Nasiry, S. (S.), de Boer, M.A. (M. A.), Groot, C.J.M. (Christianne) de, Sueters, M. (M.), Derks, J.B. (Jan), van Drongelen, J. (J.), Duvekot, J.J. (Hans), Elvan-Taspinar, A. (A.), Eyck, J. (Jim) van, van Laar, J. (J.), Morssink, L.P. (L. P.), Alfirevic, Z. (Z.), Price, L. (L.), Astor, A. (A.), Hardman, L. (L.), Sharp, A. (A.), Turner, M. (M.), Cameron, A. (A.), Draper, E. (E.), Clarke, P. (P.), Mckelvey, A. (A.), Papageorghiou, A.T. (A.), Masson, G. (G.), Aquilin, J. (J.), Johnstone, E. (E.), Bugg, G. (G.), Howe, D. (D.), Patni, S. (S.), Mousa, H. (H.), Russell, H. (H.), Hannon, T. (T.), Kilby, M.D. (Mark), David, A. (A.), Cohen, K. (K.), Impey, L. (L.), Stock, S. (S.), Poon, L. (L.), Pasupath, D. (D.), Khalil, A. (Asma), and Baker, P.N. (P. N.)

Abstract

Background: Severe, early-onset fetal growth restriction due to placental insufficiency is associated with a high risk of perinatal mortality and morbidity with long-lasting sequelae. Placental insufficiency is the result of abnormal formation and function of the placenta with inadequate remodelling of the maternal spiral arteries. There is currently no effective therapy available. Some evidence suggests sildenafil citrate may improve uteroplacental blood flow, fetal growth, and meaningful infant outcomes. The objective of the Sildenafil TheRapy In Dismal prognosis Early onset fetal growth Restriction (STRIDER) collaboration is to evaluate the effectiveness of sildenafil versus placebo in achieving healthy perinatal survival through the conduct of randomised clinical trials and systematic review including individual patient data meta-analysis. Methods: Five national/bi-national multicentre randomised placebo-controlled trials have been launched. Women with a singleton pregnancy between 18 and 30 weeks with severe fetal growth restriction of likely placental origin, and where the likelihood of perinatal death/severe morbidity is estimated to be significant are included. Participants will receive either sildenafil 25 mg or matching placebo tablets orally three times daily from recruitment to 32 weeks gestation. Discussion: The STRIDER trials were conceived and designed through international collaboration. Although the individual trials have different primary outcomes for reasons of sample size and feasibility, all trials will collect a standard set of outcomes including survival without severe neonatal morbidity at time of hospital discharge. This is a summary of all the STRIDER trial protocols and provides an example of a prospectively planned international clinical research collaboration. All five individual trials will contribute to a pre-planned systematic review of the topic including individual patient data meta-analysis.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results